ALC-0315 Toxic Metabolites: Pharmacokinetic and Regulatory Criticalities in a COVID‑19 “mRNA Vaccine”
DOI:
https://doi.org/10.56098/q9fgvp96Abstract
ALC-0315, the ionizable cationic lipid enabling the Pfizer vaccine Comirnaty’s LNP platform, is presented in regulatory files as if its metabolic fate were straightforward and well controlled. Our analysis instead identifies a basic, consequential discrepancy that should never survive dossier assembly — let alone review: the hydrolysis product dictated by the ALC-0315 chemical structure is 2-hexyldecanoic acid (α-branched), yet key submissions by Pfizer repeatedly invoke the presence of distinct 6-hexyldecanoic isomer (not commercially available, not recognized as an analytical standard in established analytical protocols). This is a material misidentification with direct safety and compliance consequences. The authentic metabolite, 2-hexyldecanoic acid, concealed by Pfizer and disguised as 6-hexyldecanoic acid, carries an H410 classification (very toxic to aquatic life with long-lasting effects), while the “phantom” 6-hexyl isomer is lacking any hazardous classification and presented as theoretically more degradable. In a CMA supporting pivotal preclinical study, substituting 2-hexyl with an unclassified 6-hexyl isomer materially compromises the clearance account, traceability, and any defensible claim of GLP grade validation for Pfizer’s vaccine. The second breakdown product (a trialkanolamine, pKa ≈ 9.6) is liable to lysosomal sequestration, thereby impeding clearance; however, the company dossier offers only limited substantiation of its disposition. Critically, the pharmacokinetic dataset does not adequately account for dose biodistribution and is predicated on insufficiently documented — or omitted — testing standards. Given the scale of exposure (billions of subjects) and the potential oncological and cardiological consequences placed on these PK criticalities, these omissions are not merely unfortunate; they are utterly unacceptable. Accordingly, we call for an independent, methodologically transparent and fully auditable re-assessment of ALC 0315 metabolism and clearance, and for all regulatory decisions concerning the Comirnaty medicinal product to be reconsidered in view of what appears to amount to a grave and consequential omission in verification procedures.
References
Abue, M., Mochizuki, M., Shibuya-Takahashi, R., Ota, K., Wakui, Y., Iwai, W., Kusaka, J., Saito, M., Suzuki, S., Sato, I., et al. (2006). Repeated COVID-19 Vaccination as a Poor Prognostic Factor in Pancreatic Cancer: A Retrospective, Single Center Cohor Study. Cancers 2025, 17, 2006. https://doi.org/10.3390/cancers17122006
Alameh, M. G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J.R., Gaudette, B.T., Soliman, O.Y., Pine, M., Hicks, P., Manzoni, T.B., Knox, J.J., Johnson, J.L., Laczkó, D., Muramatsu, H., Davis, B., Meng, W., Rosenfeld, A.M., Strohmeier, S., Lin, P., J.C., Mui, L.B., Tam, Y.K., Karikó, K., Jacquet, A., Krammer, F., Bates, P., Cancro, M.P., Weissman, D., Prak, E.T.L., Allman, D., Igyártó, B.Z., Locci, M., Pardi, N. (2021). Immunity 54(12), 2877–2892 ©2021 Elsevier Inc. https://doi.org/10.1016/j.immuni.2021.11.001
Anderson, N., Borlak, J. (2006). Drug-induced phospholipidosis. FEBS Letters, Volume 580, Issue 23, 2006, pages 5533-5540, ISSN 0014-5793. https://doi.org/10.1016/j.febslet.2006.08.061
Australian Government Department of Health. Therapeutic Goods Administration (TGA). Health Safety Regulation. Document 6. (2021). Nonclinical Evaluation Report - BNT162b2 [mRNA] COVID-19 vaccine (COMIRNATYTM). Submission No: PM-2020-05461-1-2. Sponsor: Pfizer Australia Pty Ltd. January 2021. https://www.tga.gov.au/sites/default/files/foi-2389-06.pdf
Barrera, G., Pizzimenti, S., Daga, M., Dianzani, C., Arcaro, A., Cetrangolo, GP., Giordano, G., Cucci, MA., Graf ,M., Gentile, F. (2018). Lipid Peroxidation-Derived Aldehydes, 4-Hydroxynonenal and Malondialdehyde in Aging-Related Disorders. Antioxidants (Basel). 2018 Jul 30;7(8):102. doi: 10.3390/antiox7080102. PMID: 30061536; PMCID: PMC6115986.
https://doi.org/10.3390/antiox7080102
Birdsall, R. E., Han, D., DeLaney, K., Kowalczyk, A., Cojocaru, R., Lauber, M., Le Huray, J. (2024). Monitoring stability indicating impurities and aldehyde content in lipid nanoparticle raw material and formulated drugs. Journal of Chromatography B.1570-0232/© 2024 The Author(s). Published by Elsevier B.V. https://doi.org/10.1016/j.jchromb.2024.124005
Boldyrev, I.A., Shendrikov, V.P., Vostrova, A.G. et al. (2023). A Route to Synthesize Ionizable Lipid ALC-0315, a Key Component of the mRNA Vaccine Lipid Matrix. Russ J Bioorg Chem 49, 412–415 (2023). https://doi.org/10.1134/S1068162023020061
Cheng, T., Zhao, Y., Li, X., Lin, F., Xu, Y., Zhang, X., Li, Y., Wang, R., Lai, L. Computation of octanol-water partition coefficients by guiding an additive model with knowledge. J Chem Inf Model. 2007 Nov-Dec;47(6):2140-8. Epub 2007 Nov 7. PMID: 17985865. https://doi.org/10.1021/ci700257y
Dalleau, S., Baradat, M., Guéraud, F., Huc, L. (2013). Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death Differ. 2013 Dec;20(12):1615-30. Epub 2013 Oct 4. PMID: 24096871; PMCID: PMC3824598.
https://www.nature.com/articles/cdd2013138
European Medicines Agency (EMA). (2020). Rapporteur Rolling Review critical assessment report Quality aspects COVID-19 mRNA Vaccine BioNTech. Applicant: BioNTech Manufacturing GmbH. 2020-11-19. https://factreview.s3.eu-central-1.amazonaws.com/uploads/2023/07/Rolling-Review-Report-Quality-COVID-19-mRNA-Vaccine-BioNTech.pdf
European Medicines Agency (EMA). (2021). Assessment report Comirnaty. Common name: COVID-19 mRNA vaccine (nucleoside-modified). Procedure No. EMEA/H/C/005735/0000. 19 February 2021.
European Parliament and Council of the European Union (2001). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.
https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32001L0083
European Parliament and Council of the European Union (2004). Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32004R0726
European Parliament and Council of the European Union (2008). Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32008R1272
Federico, M. (2024). The Immunologic Downsides Associated with the Powerful Translation of Current COVID-19 Vaccine mRNA Can Be Overcome by Mucosal Vaccines. Vaccines, 12(11), 1281. https://doi.org/10.3390/vaccines12111281
Fromenty, B., Pessayre, D. (1995). Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 1995;67(1):101-54. doi: 10.1016/0163-7258(95)00012-6. PMID: 7494860. https://doi.org/10.1016/0163-7258(95)00012-6
Gentilini, P., Lindsay, JC., Konishi, N., Fukushima, M., Polykretis, P. (2026). Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms. Oncotarget. 2026; 17:34-49.
https://doi.org/10.18632/oncotarget.28827
Goldman, S., Bron, D., Tousseyn, T., Vierasu, I., Dewispelaere, L., Heimann, P., Cogan, E., Goldman, M. (2021) Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report. Front. Med. 8:798095. https://doi.org/10.3389/fmed.2021.798095
Hassett, K., J., Benenato, K.E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B.M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M.J., Senn, J.J., Stanton, M.G., Almarsson, Ö., Ciaramella, G., Brito, L.A. (2019). Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Molecular Therapy: Nucleic Acids Vol. 15, 1-11 https://doi.org/10.1016/j.omtn.2019.01.013
Hilal, S.H., Karickhoff, S.W., Carreira, L.A. (2003). Prediction of chemical reactivity parameters and physical properties of organic compounds from molecular structure using SPARC. National Exposure Research Laboratory. Office of Research and Development. U.S. Environmental Protection Agency. March 2003. EPA/600/R-03/030. https://archive.epa.gov/athens/archive-athens/web/pdf/epa_600_r03_030.pdf
Hou, X., Zaks, T., Langer, R., Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nat Rev Mater 6, 1078–1094. https://doi.org/10.1038/s41578-021-00358-0
Hulscher, N., Hodkinson, R., Makis, W., McCullough, P. (2024). Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis. ESC Heart Fail. 2025 Oct;12(5):3212-3225. doi: 10.1002/ehf2.14680. Epub 2024 Jan 14. PMID: 38221509; PMCID: PMC12450757. https://pubmed.ncbi.nlm.nih.gov/38221509/
Jablonowski, K., Hooker, B. S. (2022). Delayed Vigilance: A Comment on Myocarditis in Association with the COVID-19 Injections. (2022). International Journal of Vaccine Theory, Practice, and Research , 2(2), 651.1-651.4. https://doi.org/10.56098/ijvtpr.v2i2.61
Kelley, N., Jeltema, D., Duan, Y., He, Y. (2019). The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019 Jul 6;20(13):3328. doi: 10.3390/ijms20133328. PMID: 31284572; PMCID: PMC6651423. https://doi.org/10.3390/ijms20133328
Khan, H. (2024). UHPLC-MS/MS Technique: Applications in Analytical Chemistry. Asian Journal of Chemistry; Vol. 36, No. 4 (2024), 766-778. https://doi.org/10.14233/ajchem.2024.31383
Kuperwasser, C., El-Deiry, WS. (2026). COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms. Oncotarget. 2026. 17:1–29. https://doi.org/10.18632/oncotarget.28824 .[PubMed]
Ioannidis, M., Tjepkema, J., Uitbeijerse, M. R.P., van den Bogaart, G. (2025). Immunomodulatory effects of 4-hydroxynonenal. Redox Biology, Volume 85, September 2025, 103719, ISSN 2213-2317. https://doi.org/10.1016/j.redox.2025.103719
Li, Y., Zhao, T., Li, J., Xia, M., Li, Y., Wang, X., Liu, C., Zheng, T., Chen, R., Kan, D., Xie, Y., Song, J., Feng, Y., Yu, T., Sun, P. (2022). Oxidative Stress and 4-hydroxy-2-nonenal (4-HNE): Implications in the Pathogenesis and Treatment of Aging-related Diseases. J Immunol Res. 2022 Mar 23;2022:2233906. doi: 10.1155/2022/2233906. PMID: 35411309; PMCID: PMC8994689.
Marik, P., Hope, J. (2025). COVID-19 mRNA-Induced "Turbo Cancers". J Indep Med 2025 Vol. 1 No. 3.
https://doi.org/10.71189/JIM/2025/V01N03A02
Mead, M.N., Seneff, S., Wolfinger, R., Rose, J., Denhaerynck, K., Kirsch, S., McCullough, P. A. (2024). COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1. (2024). International Journal of Vaccine Theory, Practice, and Research , 3(2), 1112-1178.
https://doi.org/10.56098/fdrasy50
Mead, M.N., Seneff, S., Rose, J., Wolfinger, R., Hulscher, N., McCullough, P. A. (2024). COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2. (2024). International Journal of Vaccine Theory, Practice, and Research , 3(2), 1275-1344.
https://doi.org/10.56098/w66wjg87
Mohsin, N.u.A., Farrukh, M., Shahzadi, S., Irfan, M. (2024). Drug Metabolism: Phase I and Phase II Metabolic Pathways. Drug Metabolism and Pharmacokinetics. IntechOpen. Edited by Mithun Rudrapal.
DOI: 10.5772/intechopen.112854. https://www.intechopen.com/chapters/88053
Mulroney, T.E, Pöyry, T., Yam-Puc, J.C., Rust, M., Harvey, R.F., Kalmar, L., Horner, E., Booth, L., Ferreira, A.P., Stoneley, M., Sawarkar, R., Mentzer, A.J., Lilley, K.S., Smales, C.M., von der Haar, T., Turtle, L., Dunachie, S., Klenerman, P., Thaventhiran, JED., Willis, A.E. (2024). N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature. 2024 Jan;625(7993):189-194. Epub 2023 Dec 6. PMID: 38057663; PMCID: PMC10764286. https://doi.org/10.1038/s41586-023-06800-3
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., Igyarto, B.Z. (2021). The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479. https://doi.org/10.1016/j.isci.2021.103479
Oster, ME., Shay, DK., Su, JR., Gee, J., Creech, CB., Broder, KR., Edwards, K., Soslow, JH., Dendy, JM., Schlaudecker, E., Lang, SM., Barnett, ED., Ruberg, FL., Smith, MJ., Campbell, MJ., Lopes ,RD., Sperling, LS., Baumblatt, JA., Thompson, DL., Marquez, PL., Strid, P., Woo, J., Pugsley, R., Reagan-Steiner, S., DeStefano, F., Shimabukuro, TT. (2022). Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022 Jan 25;327(4):331-340. PMID: 35076665; PMCID: PMC8790664. https://doi.org/10.1001/jama.2021.24110 Oster
Palmer, M., Bhakdi, S., Wodarg, W. (2022). Expertise on the genotoxic risks of the Pfizer COVID-19 vaccine.
Parry, P.I., Lefringhausen, A., Turni, C., Neil, C.J., Cosford, R., Hudson, N.J., Gillespie, J. (2023). ‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. Biomedicines 2023, 11, 2287. https://doi.org/10.3390/biomedicines11082287
Patel, P., Ibrahim, N.M., Cheng, K. (2021). The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA. Trends in Pharmacological Sciences, 42(6), 448–460. https://doi.org/10.1016/j.tips.2021.03.002
Pfizer. (2020). Investigation of the Biotransformation of ALC-0159 and ALC-0315 In vitro and in vivo in rats. PF-07302048 Biotransformation. PF-07302048_05Aug20_043725.
https://phmpt.org/wp-content/uploads/2023/02/125742_S1_M4_4.2.2.4-043725.pdf
Prakash, S. (2018). Beta (β)-Oxidation of Fatty Acid and its associated Disorders. Vol. 5 (1), pp. 158-172, December, 2018. Global Science Research Journals. International Journal of Clinical Biochemistry.
Rajman, L., Chwalek, K., Sinclair, D. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism. Cell Press. ; 27, 529-547. March 06, 2018. https://doi.org/10.1016/j.cmet.2018.02.011
Rowland, A., Miners, J.O., Mackenzie, P.I. (2013 ). The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013 Jun;45(6):1121-32. doi: 10.1016/j.biocel.2013.02.019. Epub 2013 Mar 7. PMID: 23500526. https://www.sciencedirect.com/science/article/abs/pii/S1357272513000654?via%3Dihub
Rubbens, J., Wille, S., Samyn, N. (2022). Sample preparation and quantitative UHPLC-MS/MS analysis in an accredited high-throughput environment: Tips and tricks to improve your success ratio. Elsevier. Toxicologie Analytique et Clinique.
Volume 34, Issue 3, Supplement, September 2022, Page S162. https://doi.org/10.1016/j.toxac.2022.06.277
Rubio-Casillas, A., Cowley, D., Raszek, M., Uversky, VN., Redwan, EM. (2024). Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer? Int J Biol Macromol. 2024 May;267(Pt 1):131427. doi: 10.1016/j.ijbiomac.2024.131427. Epub 2024 Apr 5. Erratum in: Int J Biol Macromol. 2024 Jun;270(Pt 2):132447.2024.132447. PMID: 38583833.
https://doi.org/10.1016/j.ijbiomac.2024.131427
Saadati, F., Cammarone, S., Ciufolini, M. A. (2022). A Route to Lipid ALC-0315: a Key Component of a COVID-19 mRNA Vaccine. Chem. Eur. J.2022, 28, e202200906. https://doi.org/10.1002/chem.202200906
Sanjeev, R., Jagannadham, V., Skelton, A., Sreedhar, P., Bethapudi, V., E., M., Vrath, R., V. (2017). Taft Equation - A Convenient Tool to Decide the Position of Attack in the Reactions of Aliphatic Amines and Tl (III). Orient J Chem 2017;33(5). https://www.orientjchem.org/vol33no5/role-of-taft-equation-in-selecting-the-site-of-attack-in-the-reactions-of-aliphatic-amines-and-tliii/#:~:text=Introduction,steric%20and%20polar%20contributions%20effect.
Santiago, D., Oller, J. W. (2023). Abnormal Clots and All-Cause Mortality During the Pandemic Experiment: Five Doses of COVID-19 Vaccine Are Evidently Lethal to Nearly All Medicare Participants . (2023). International Journal of Vaccine Theory, Practice, and Research , 3(1), 847-890. https://doi.org/10.56098/ijvtpr.v3i1.73
Schulz, H. (2002). Oxidation of fatty acids in eukaryotes. Elsevier. New Comprehensive Biochemistry. Volume 36, 2002, Pages 127-150. https://doi.org/10.1016/S0167-7306(02)36007-1
Segalla, G. (2023a). Chemical-physical criticality and toxicological potential of lipid nanomaterials contained in a COVID- 19 mRNA vaccine. International Journal of Vaccine Theory, Practice, and Research, 3(1), 787–817.
https://doi.org/10.56098/ijvtpr.v3i1.68
Segalla, G. (2023b). Apparent Cytotoxicity and Intrinsic Cytotoxicity of Lipid Nanomaterials Contained in a COVID-19 mRNA Vaccine. International Journal of Vaccine Theory, Practice, and Research , 3(1), 957-972. https://doi.org/10.56098/ijvtpr.v3i1.84
Segalla, G. (2024). Adjuvant Activity and Toxicological Risks of Lipid Nanoparticles Contained in the COVID‑19 “mRNA Vaccines”. International Journal of Vaccine Theory, Practice, and Research , 3(2), 1085-1102. https://doi.org/10.56098/z1ydjm29
Shcherbik, N., Pestov, D.G. (2019). The Impact of Oxidative Stress on Ribosomes: Cells. 2019; 8(11):1379. https://doi.org/10.3390/cells8111379
Shoeb, M., Ansari, NH., Srivastava, SK., Ramana, KV. (2014). 4-Hydroxynonenal in the pathogenesis and progression
of human diseases. Curr Med Chem. 2014;21(2):230-7. PMID: 23848536; PMCID: PMC3964795.
http://dx.doi.org/10.2174/09298673113209990181
Sterz, H. (2026). DIE IMPF-MAFIA [The Vaccination Mafia]. ISBN 978-3-907606-00-1 - 5th edition 2026. Rubikon-Verlag GmbH, Basel. Book Review by Prof. Harald Walach: https://harald-walach.info/2025/11/27/book-review-helmut-sterz-the-vaccination-mafia/
Sudbrack, T. P., Archilha, N. L., Itri, R., & Riske, K. A. (2011). Observing the Solubilization of Lipid Bilayers by Detergents with Optical Microscopy of GUVs. The Journal of Physical Chemistry B, 115(2), 269–277. https://pubs.acs.org/doi/10.1021/jp108653e
Swaminathan, G., Thoryk, E.A., Cox, K.S., Meschino, S., Dubey, S.A., Vora, K.A., Celano, R., Gindy, M., Casimiro, D.R., and Bett, A.J. (2016a). A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens. Vaccine 34, 110–119. https://doi.org/10.1016/j.vaccine.2015.10.132
Swaminathan, G., Thoryk, E.A., Cox, K.S., Smith, J.S., Wolf, J.J., Gindy, M.E., Casimiro, D.R., and Bett, A.J. (2016b). A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates. Sci. Rep. 6, 34215. https://doi.org/10.1038/srep34215
Tahtinen, S., Tong, AJ., Himmels, P. et al. (2022) IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol 23, 532–542. https://doi.org/10.1038/s41590-022-01160-y
Tizard, I. R. (2020). Vaccines for Veterinarians. Chapter 7, Adjuvants and adjuvanticity, 75-86, ISBN 978-0-323-68299-2, Elsevier, https://doi.org/10.1016/C2018-0-01755-7
Verbeke, R., Hogan, M. J., Lore, K., Pardi, N. (2022). Innate immune mechanisms of mRNA vaccines. Cell Press, Review. Immunity 55, 1993-2005. https://doi.org/10.1016/j.immuni.2022.10.014
Willi, J., Küpfer, P., Evéquoz, D., Fernandez, G., Katz, A., Leumann, C., Polacek, N. (2018). Oxidative stress damages rRNA inside the ribosome and differentially affects the catalytic center. Nucleic Acids Research, Volume 46, Issue 4, 28 February 2018, Pages 1945–1957.
https://doi.org/10.1093/nar/gkx1308
Xie, N., Zhang, L., Gao, W. et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Sig Transduct Target Ther 5, 227 (2020). https://doi.org/10.1038/s41392-020-00311-7
Yu, CK., Tsao, S., Ng, CW., Chua, GT., Chan, KL., Shi, J., Chan, YY., Ip, P., Kwan, MY., Cheung, YF. (2023). Cardiovascular Assessment up to One Year After COVID-19 Vaccine-Associated Myocarditis. Circulation. 2023 Aug;148(5):436-439. Epub 2023 Jul 31. PMID: 37523760; PMCID: PMC10373639.
https://doi.org/10.1161/circulationaha.123.064772
Yonker, LM., Swank, Z., Bartsch, YC., Burns, MD., Kane, A., Boribong, BP., Davis, JP., Loiselle, M., Novak, T., Senussi, Y., Cheng, CA., Burgess, E., Edlow, AG., Chou, J., Dionne, A., Balaguru, D., Lahoud-Rahme, M., Arditi, M., Julg, B., Randolph, AG., Alter, G., Fasano, A., Walt, DR. (2023). Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis. Circulation. 2023 Mar 14;147(11):867-876. Epub 2023 Jan 4. PMID: 36597886; PMCID: PMC10010667. https://doi.org/10.1161/circulationaha.122.061025
Yu, Z., Li, Q., Wang, J., Yu, Y., Wang, Y., Zhou, Q. (2020). Reactive Oxygen Species- Related Nanoparticle Toxicity in the Biomedical Field - Nanoscale Res Lett 15, 115
https://doi.org/10.1186/s11671-020-03344-7
Yasmin, F., Najeeb, H., Naeem, U., Moeed, A., Atif, A.R., Asghar, M.S., Nimri, N., Saleem, M., Bandyopadhyay, D., Krittanawong, C., Fadelallah Eljack, M.M., Tahir, MJ., Waqar, F. (2023). Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023 Mar;11(3):e807. doi: 10.1002/iid3.807. PMID: 36988252; PMCID: PMC10022421. https://pubmed.ncbi.nlm.nih.gov/36988252/
Yun, C.H., Bae, C.S., & Ahn, T. (2016). Cargo-Free Nanoparticles Containing Cationic Lipids Induce Reactive Oxygen Species and Cell Death in HepG2 Cells - Biol Pharm Bull. 39(8):1338-46 https://doi.org/10.1248/bpb.b16-00264
Zaman, M., Good, M.F., Toth, I. (2013). Nanovaccines and their mode of action. Methods, 60(3), 226-231. https://doi.org/10.1016/j.ymeth.2013.04.014
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Gabriele Segalla
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright for materials in this journal, IJVTPR, is owned by the author. The author, however, grants first right of publication to the journal, IJVTPR and assures the editorial staff of the journal that the work submitted has not simultaneously been submitted to any other journal, nor is it under consideration for publication by any other journal. If any portion of the work submitted has appeared elsewhere, the quoted material is properly cited and credit is given to the original publisher. The submitting author (or the principal and corresponding author of the work) also assures the editors of IJVTPR that he or she has obtained all required written permissions from any quoted authors or publishers of quoted materials. The submitting author also agrees to hold IJVTPR and its editorial staff harmless from any infractions of copyright law that may be discovered at any time in the future in the submitted work. The author assures the editorial staff at IJVTPR that none of the work submitted is plagiarized, and that any recycled or precycled material by the author is identified as such with proper credits in the text to any other parties holding a copyright interest in the quoted material.